Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genelabs, Syntello Inc. deal

Mark Van Asten, director of business development in GNLB's diagnostic division, said GNLB received an exclusive license because

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE